Phase II trials in mesothelioma: An increasing challenge
- 31 October 2005
- journal article
- editorial
- Published by Elsevier in Lung Cancer
- Vol. 50 (1) , 87-90
- https://doi.org/10.1016/j.lungcan.2005.05.024
Abstract
No abstract availableThis publication has 24 references indexed in Scilit:
- A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesotheliomaLung Cancer, 2005
- Chemotherapy options and new advances in malignant pleural mesotheliomaAnnals of Oncology, 2005
- FDA Drug Approval Summaries: Pemetrexed (Alimta®)The Oncologist, 2004
- Staging and response to therapy of malignant pleural mesotheliomaLung Cancer, 2004
- Chemotherapy for malignant pleural mesothelioma: past results and recent developmentsLung Cancer, 2004
- Modified RECIST criteria for assessment of response in malignant pleural mesotheliomaAnnals of Oncology, 2004
- Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesotheliomaLung Cancer, 2004
- Staging and evaluating responses in malignant pleural mesotheliomaLung Cancer, 2004
- Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural MesotheliomaJournal of Clinical Oncology, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000